Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Kimberly A. Mcgregor

Oncology
Trinity Health
831 S Broadway, 
Minot, ND 

Experienced in WT1-Related Wilms Tumor Syndromes
Trinity Health
831 S Broadway, 
Minot, ND 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kimberly Mcgregor is an Oncologist in Minot, North Dakota. Dr. Mcgregor is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CO
Hospital Affiliations
Intermountain Health St. Mary's Regional Hospital
Trinity Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

TRINITY HEALTH
831 S Broadway, Minot, ND 58701
Call: 701-418-8000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

2 Total Publications

CGE25-111: Enhancing Oncology Treatment Personalization through Plasma Proteomics and Machine Learning.
CGE25-111: Enhancing Oncology Treatment Personalization through Plasma Proteomics and Machine Learning.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
View All 2 Publications
Similar Doctors
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Moayed A. Ibrahim
Hematology Oncology | Hematology | Oncology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Moayed A. Ibrahim
Hematology Oncology | Hematology | Oncology

Trinity Health

831 S Broadway, 
Minot, ND 
 (0.1 miles away)
701-418-8000
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Moayed Ibrahim is a Hematologist Oncology specialist and a Hematologist in Minot, North Dakota. Dr. Ibrahim is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Pancreatic Cancer, Chronic Lymphocytic Leukemia (CLL), Paget Disease of the Breast, and Muscle Invasive Bladder Cancer. Dr. Ibrahim is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcgregor's expertise for a condition
ConditionClose
      • Advanced
      • Angiosarcoma
        Dr. Mcgregor is
        Advanced
        . Learn about Angiosarcoma.
        See more Angiosarcoma experts
      • Breast Cancer
        Dr. Mcgregor is
        Advanced
        . Learn about Breast Cancer.
        See more Breast Cancer experts
      • Inflammatory Breast Cancer
        Dr. Mcgregor is
        Advanced
        . Learn about Inflammatory Breast Cancer.
        See more Inflammatory Breast Cancer experts
      • Paget Disease of the Breast
        Dr. Mcgregor is
        Advanced
        . Learn about Paget Disease of the Breast.
        See more Paget Disease of the Breast experts
      • Experienced
      • Adult Soft Tissue Sarcoma
        Dr. Mcgregor is
        Experienced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • Agranulocytosis
        Dr. Mcgregor is
        Experienced
        . Learn about Agranulocytosis.
        See more Agranulocytosis experts
      • ALK-Positive Non-Small Cell Lung Cancer
        Dr. Mcgregor is
        Experienced
        . Learn about ALK-Positive Non-Small Cell Lung Cancer.
        See more ALK-Positive Non-Small Cell Lung Cancer experts
      • Carcinoid Syndrome
        Dr. Mcgregor is
        Experienced
        . Learn about Carcinoid Syndrome.
        See more Carcinoid Syndrome experts
      • Cholangiocarcinoma (Bile Duct Cancer)
        Dr. Mcgregor is
        Experienced
        . Learn about Cholangiocarcinoma (Bile Duct Cancer).
        See more Cholangiocarcinoma (Bile Duct Cancer) experts
      • Chromophobe Renal Cell Carcinoma
        Dr. Mcgregor is
        Experienced
        . Learn about Chromophobe Renal Cell Carcinoma.
        See more Chromophobe Renal Cell Carcinoma experts
      View All 37 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2025 All Rights Reserved